Join
Live feed
·
PRReleasevia Quantisnow
Kezar Life Sciences Inc. logo

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

ByQuantisnow·Wall Street's wire, on your screen.
KZR· Kezar Life Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KZR (Kezar Life Sciences Inc.) and more on Quantisnow.